Managers / Q3 2019 · view latest →
Foresite Capital Management IV, LLC
CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management IV, LLC reported $309M in U.S.-listed holdings across 19 positions for Q3 2019.
The portfolio is heavily concentrated: Turning Point Therapeutics alone accounts for 22.2% of reported value.
Compared with Q2 2019, the fund opened 2 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 64.9% · $201M
- Other · 33.0% · $102M
- ADR · 2.1% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| FULCFulcrum Therapeutics, Inc. | NEW | +1.69M | 1.69M | +$11M | $11M |
| Orchard Therapeutics PLC | NEW | +557.7K | 557.7K | +$7M | $7M |
| REPLReplimune Group, Inc. | SOLD OUT | −1.23M | 0 | −$18M | $0 |
| NGM Biopharmaceuticals, Inc. | SOLD OUT | −471.3K | 0 | −$7M | $0 |
| VCYTVeracyte, Inc. | SOLD OUT | −200.0K | 0 | −$6M | $0 |
| ABUSArbutus Biopharma Corporation | SOLD OUT | −608.2K | 0 | −$1M | $0 |
| Kiniksa Pharmaceuticals, Ltd. | SOLD OUT | −63.9K | 0 | −$866,000 | $0 |
| Aerie Pharmaceuticals, Inc. | ADDED | +800.9K | 1.60M | +$7M | $31M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Turning Point Therapeutics, Inc. | COM | 22.19% | $69M | 1.83M |
| 2 | Aerie Pharmaceuticals, Inc. | COM | 8.70% | $27M | 1.40M |
| 3 | INSMInsmed Incorporatedhistory → | COM | 8.15% | $25M | 1.43M |
| 4 | The Medicines Company | COM | 7.73% | $24M | 478.2K |
| 5 | ASNDAscendis Pharma A/Shistory → | SPONSORED ADR | 7.64% | $24M | 245.4K |
| 6 | CYTKCytokinetics Incorporatedhistory → | COM NEW | 6.98% | $22M | 1.90M |
| 7 | Biohaven Pharmaceutical Holding Company Ltd. | COM | 5.74% | $18M | 425.8K |
| 8 | OptiNose, Inc. | COM | 5.06% | $16M | 2.24M |
| 9 | VYGRVoyager Therapeutics, Inc.history → | COM | 4.62% | $14M | 830.6K |
| 10 | ALECAlector, Inc.history → | COM | 4.36% | $14M | 936.4K |
| 11 | Myokardia, Inc. | COM | 4.01% | $12M | 238.2K |
| 12 | FULCFulcrum Therapeutics, Inc.history → | COM | 3.62% | $11M | 1.69M |
| 13 | CymaBay Therapeutics, Inc. | COM | 3.41% | $11M | 2.06M |
| 14 | Orchard Therapeutics PLC | ADS | 2.14% | $7M | 557.7K |
| 15 | RYTMRhythm Pharmaceuticals, Inc.history → | COM | 1.64% | $5M | 234.5K |
| 16 | IMMUImmunomedics, Inc.history → | COM | 1.58% | $5M | 367.6K |
| 17 | SIBNSI-BONE, Inc.history → | COM | 1.17% | $4M | 205.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $237M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $230M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $183M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $124M | 6 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $111M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $109M | 4 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $153M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $149M | 4 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $198M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $198M | 5 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $180M | 7 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $203M | 7 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $193M | 8 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $234M | 8 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $311M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $371M | 8 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $357M | 9 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $486M | 9 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $679M | 12 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $740M | 13 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $835M | 13 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $921M | 13 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $443M | 15 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $205M | 12 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $81M | 11 | May 28, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2019 | $232M | 14 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $309M | 19 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $354M | 22 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $278M | 16 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.